tbuckley/cabot-search huggingface dataset:
Spin
Authors: John Savoie
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tuberculous Addison's Disease and Thyrotoxicosis
Authors: Chris P. Casten, William D. Towne
Journal: JAMA (1978)

Addison's disease developed in two patients after they had tuberculosis. Thyrotoxicosis subsequently developed. In both cases, the adrenal glands were calcified, suggesting that Addison's disease was tuberculous in origin. Results of tests for antithyroglobulin, antimicrosomal, and adrenal cortex antibodies were normal. These findings do not suggest an autoimmune basis for the occurrence of the two endocrinopathies. The rarity of the simultaneous occurrence of both disorders suggests it to be fortuitous. (<i>JAMA</i>239:2014-2015, 1978)
417P Availability and Utility of Functional Imaging (FI) and Peptide Receptor Radionuclide Therapy (PRRT) in the CommNETS Collaboration (Australia, Canada and New Zealand)
Authors: B.A. Chan, H.-W. Sim, A. Ravikumar, D. Bailey, D. Chan, B. Lawrence, A. McEwan, N. Pavlakis, E. Segelov, S. Singh, P. Roach, D. Wyld
Journal: Annals of Oncology (2016)
Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations
Authors: H. S. Margolis
Journal: JAMA (1995)

<h3>Objective.</h3> —To evaluate the outcome of immunization strategies to prevent hepatitis B virus (HBV) transmission. <h3>Design and Setting.</h3> —A decision model was used to determine the incremental effects of the following hepatitis B immunization strategies in a birth cohort receiving immunization services in the public sector: (1) prevention of perinatal HBV infection, (2) routine infant vaccination, or (3) routine adolescent vaccination. <h3>Main Outcome Measures.</h3> —Over the lifetime of the cohort, the reduction in infections and medical and work-loss costs of HBV-related liver disease were determined for each strategy and compared with the outcome without immunization. <h3>Results.</h3> —Prevention of perinatal infection and routine infant vaccination would lower the 4.8% lifetime risk of HBV infection by at least 68%, compared with a 45% reduction for adolescent vaccination. From a societal perspective, each strategy was found to be cost saving, but was not cost saving with respect to direct medical costs. The estimated cost per year of life saved was $164 to prevent perinatal HBV infection, $1522 for infant vaccination, and $3730 for adolescent vaccination. <h3>Conclusions.</h3> —Routine vaccination of infants in successive birth cohorts to prevent HBV transmission is cost-effective over a wide range of assumptions. While economically less attractive than infant vaccination, adolescent vaccination could serve to protect those children who were not vaccinated as infants. (<i>JAMA</i>. 1995;274:1201-1208)
Organotherapy
Authors: Mark S. Bernhardt
Journal: JAMA Dermatology (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
342 INTRAHEPATIC IL-8 PRODUCING CD4+ REGULATORY T CELLS AND FIBROGENESIS IN CHRONIC HEPATITIS C
Authors: B. Langhans, S. Arndt, I. Braunschweiger, B. Krämer, R. Hüneburg, S. Manekeller, T. Sauerbruch, U. Spengler
Journal: Journal of Hepatology (2013)
SIR MICHAEL FOSTER (1836-1907)
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Progress in medical defense against nerve agents
Authors: M. A. Dunn
Journal: JAMA (1989)

For nearly 50 years, nerve agents have constituted a serious threat that has stimulated extensive efforts to develop effective medical countermeasures. Recent progress in producing pharmacologic defenses suggests that humans can be largely protected from the lethal and prolonged incapacitating effects of these compounds on a chemical battlefield. Current research on new approaches to binding and inactivating nerve agents may further decrease their potential as a threat against protected persons. (<i>JAMA</i>. 1989;262:649-652)
LOST GENERATIONS
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Third Annual Symposium on Advances in Cancer Treatment Research
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Third Annual Symposium on Advances in Cancer Treatment Research Get access JNCI: Journal of the National Cancer Institute, Volume 59, Issue 6, December 1977, Page 1755, https://doi.org/10.1093/jnci/59.6.1755 Published: 01 December 1977
Report of the Ninth Duke University Medical Center Private Sector Conference
Authors: John K. Iglehart
Journal: New England Journal of Medicine (1984)

Relations between American hospitals and their medical staffs, increasingly troubled because of conflicting imperatives that society has imposed through its major agent of change — the federal government — will grow worse before they stand much chance of general improvement. Creation of a Medicare payment mechanism that essentially places a hospital at financial risk for the behavior of its medical staff is the latest government action to upset these relations, but other forces are also placing strains on the collaboration between institutional and individual providers of care, including a growing supply of physicians, an increasing inclination by hospital medical staffs . . .
Cell cycLe inhibitiON to target the EVolution of urOthelial cancer (CLONEVO): A single-arm, open-label window-of-opportunity trial of neoadjuvant abemaciclib in platinum-ineligible muscle invasive bladder cancer patients.
Authors: Jones Nauseef, Panagiotis J. Vlachostergios, Ana M. Molina, David M. Nanus, Cora N. Sternberg, Timothy D McClure, Douglas Scherr, M. Laura Martin, Giorgio Inghirami, Olivier Elemento, Scott T. Tagawa, Bishoy Morris Faltas
Journal: Journal of Clinical Oncology (2020)

TPS5096 Background: The standard of care for clinically localized muscle-invasive bladder cancer (MIBC) is neoadjuvant platinum-based combination chemotherapy followed by radical cystectomy (RC). Up to 40% of patients (pts) are ineligible to receive cisplatin and proceed to RC without any neoadjuvant therapy. We and others have demonstrated enrichment of molecular alterations in cell cycle genes in MIBC, including copy number losses of CDKN2A in 41% of pts. Abemaciclib is a unique CDK4/6 inhibitor with single agent activity and a target kinome distinct from other CDK4/6 inhibitors. We have demonstrated that CRISPR knockout of CDKN2A increases susceptibility to abemaciclib in bladder cancer cell lines. Beyond tumor-intrinsic effects, abemaciclib also modulates the tumor microenvironment (TME) via upregulating human endogenous retroviral elements and increasing T cell infiltration. Methods: Cell cycLe inhibitiON to target the EVolution of urOthelial cancer (CLONEVO) is a single arm, window-of-opportunity trial of neoadjuvant abemaciclib which will evaluate tumor cell and TME changes in response to abemaciclib. Enrolled pts must be ineligible for platinum-based neoadjuvant therapy for resectable MIBC. Pts receive abemaciclib (200 mg BID PO) for 4 weeks prior to RC. Tumor tissue collected via transurethral resection of bladder tumor (TURBT) and residual tumor at RC undergo single cell RNA sequencing and whole-exome sequencing. Patient-derived organoids and xenografts are generated for a co-clinical trial of abemaciclib alone or in combination. The primary endpoint is the measurement of changes in cell cycle dynamics. Secondary objectives are assessment of toxicity via NCI CTCAE v 5.0 and pathologic downstaging of MIBC. We will perform targeted sequencing of a panel of cell cycle genes in serial plasma and urine cell free DNA to evaluate changes in the variant allele fractions of somatic alterations. The novel design of this trial allows dynamic in vivo assessment of tumor changes and creates a new paradigm for studying tumor evolution in real time. Clinical trials information: NCT03837821. Clinical trial information: NCT03837821 .
LIGHT AND THE EFFECTS OF VITAMIN A
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction
Journal: Circulation (2011)

On page 2623, in the first column, under "5.4.Mediastinitis/Perioperative Infection," the second recommendation under Class I read, 2. A second-generation cephalosporin is recommended for prophylaxis in patients without methicillin-resistant Staphylococcus aureus colonization. 353-361(Level of Evidence: A) It has been changed to read, 2. A first-or second-generation cephalosporin is recommended for prophylaxis in patients without methicillin-resistant Staphylococcus aureus colonization.
Traité de Pathologie Médicale et Thérapeutique Appliquée.
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Steroid-induced pancreatitis
Authors: R. W. Schrier
Journal: JAMA (1965)

THE COMPLICATIONS of therapy with adrenocortical hormones have been reviewed extensively, but the pancreatic abnormalities which occur in association with administration of steroids rarely have been included.<sup>1</sup> A postmortem study by Carone and Liebow<sup>2</sup>revealed histologic evidence of acute pancreatitis, or peripancreatic fat necrosis, in 16 of 54 patients treated with corticotropin or adrenal steroids. In a control group of 54 patients of comparable age and with similar major diseases, only two had these pathologic changes. The clinical diagnosis of pancreatitis was not made in any of these patients. In 1961 Nelp<sup>3</sup>reviewed the literature and reported six of his own cases of clinically manifest acute pancreatitis associated with the administration of adrenal steroids. To our knowledge, no additional cases have been reported. In 12 of 14 previously reported instances of symptomatic pancreatitis induced by steroids, the diagnosis was not made until exploratory surgery or autopsy.<sup>3-8</sup>
A novel test and treat hepatitis C micro-elimination project among underserved communities in Islamabad, Pakistan
Authors: Huma Qureshi, Hassan Mahmood, Nabil Ahmed, Jacqueline Safstrom, Lillian Lou, Muazzam Nasrullah, Francisco Averhoff, Ameer Abutaleb, Shyamasundaran Kottilil
Journal: Journal of Hepatology (2020)
Germs
Authors: Lewis Thomas
Journal: New England Journal of Medicine (1972)

WATCHING television, you'd think we lived at bay, in total jeopardy, surrounded on all sides by human-seeking germs, shielded against infection and death only by a chemical technology that enables us to keep killing them off. We are instructed to spray disinfectants everywhere, into the air of our bedrooms and kitchens and with special energy into bathrooms, since it is our very own germs that seem the worst kind. We explode clouds of aerosol, mixed for good luck with deodorants, into our noses, mouths, underarms, privileged crannies — even into the intimate insides of our telephones. We apply potent antibiotics . . .
Die Individualität des Blutes in der Biologie, in der Klinik und in der gerichtlichen Medizin.
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diagnostic and therapeutic technology assessment. Cardiokymography
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Liver stiffness measurement by fibroscan predicts the occurrence of liver-related events and death in patients with NAFLD-related compensated advanced chronic liver disease
Authors: Salvatore Petta, Giada Sebastiani, Mauro Viganò, Vincent Wai-Sun Wong, Jerome Boursier, Annalisa Berzigotti, Elisabetta Bugianesi, Anna Ludovica Fracanzani, Manuel Romero Gomez, Calogero Camma, Vito Di Marco, Marraud des Grottes, Ramy Younes, Aline Keyrouz, Rosa Lombardi, Yuly Mendoza, Grazia Pennisi, Antonio Craxi, Victor de Lédinghen
Journal: Journal of Hepatology (2020)
Abstract 3137: E-cadherin is a useful surrogate maker to predict chemosensitivity of neoadjuvant chemotherapy for breast cancer
Authors: Naoki Aomatsu, Masakazu Yashiro, Shinichiro Kashiwagi, Tsutomu Takashima, Hidemi Kawajiri, Naoyoshi Onoda, Tetsuro Ishikawa, Kosei Hirakawa
Journal: Cancer Research (2011)

Abstract Background: Current studies have demonstrated that neoadjuvant chemotherapy (NAC) improves the prognosis of patients with breast cancer, however, no reliable maker to predict chemosensitivity of NAC is not available. Although E-cadherin is one of the markers for chemosensitivity in several types of carcinomas, the significance of E-cadherin for chemosensitivity of NAC remains unclear. The aim of this study was to evaluate the value of E-cadherin as a surrogate maker of NAC for breast cancer. Experimental Design: A total of 104 patients with breast cancer of stage II and III, as evaluated by core needle biopsy and ultrasonography, was treated with NAC, including FEC (5-fluorouracil + epirubicin + cyclophosphamide) followed by weekly paclitaxel. Expressions of E-cadherin, estrogen receptor, progesterone receptor, and HER2 were assessed by immunohistochemistry. Clinical responses and pathological responses were classified according to WHO criteria or The General Rules for Breast Cancer. Results: A clinical response (responder; complete response + partial response) was observed in 93 (89%) of 104 patients. The pathological complete response rate (pCR) was 29% (30/104). E-cadherin was positive in 60 (57%) of 104 breast cancer. Fifty-eight (96%) of 60 E-cadherin-positive tumors were responders, while 35 (80%) of 44 E-cadherin-negative tumors were non-responders (p=0.005). The pCR rate (37%; 22/60) of E-cadherin-positive tumors also was significantly (p=0.04) higher than that (18%; 8/44) of E-cadherin-negative tumors. Among the 104 breast cancer cases, 32 (31%) revealed a triple-negative phenotype (estrogen receptor-negative, progesterone receptor-negative, and HER2-negative). The pCR of triple-negative breast cancer was 34% (11/32). In the 32 triple-negative breast cancers, the pCR rate (64%; 7/11) of E-cadherin-positive tumors was significantly (p=0.004) higher than that (19%; 4/21) of E-cadherin-negative tumors.Conclusion: E-cadherin might be a clinically useful maker to predicting the response to NAC in breast cancer, especially in triple-negative breast cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3137. doi:10.1158/1538-7445.AM2011-3137